April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.
Phase III trial results show that once-daily brensocatib reduces pulmonary exacerbations and slows lung function decline in patients with bronchiectasis.
Researchers combined spatial transcriptomics with machine learning to develop a urine-based prostate cancer test with 92% accuracy, outperforming traditional PSA testing.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
Researchers found Oropouche virus to be underreported during a large-scale study across Latin America, with climate emerging as the primary driver of transmission risk.